An ancient RNA-guided system could simplify delivery of gene editing therapies | Broad Institute
broadinstitute.org · 561 words · saved by 1 readers
The programmable proteins are compact, modular, and can be directed to modify DNA in human cells.
Broad Institute's gene-editing technologies—CRISPR-Cas9, base editing, and prime editing—are being tested in more than 25 clinical trials to treat or cure leukemias, rare genetic diseases, high cholesterol, and other conditions. NIH-funded discoveries from the Broad Institute are powering nearly 20 clinical trials from companies testing new treatments for diseases like cancer and heart disease. Broad Institute developed a technology — partly supported by NIH funding — that can detect trace amounts of cancer DNA from blood tests and help cancer patients find out their risk of disease…
related reading
- CRISPR Gene Therapy: Applications, Limitations, and Implications for the Futurencbi.nlm.nih.gov
- George Church: The Future Without Limit | Innovators | National Geographicnationalgeographic.com
- Gene Genies: Inside The Revolutionary Biotech That Can Edit DNA Inside Living Humansforbes.com
- Evo 2 Can Design Entire Genomesasimov.press
- Powerful CRISPR system inserts whole gene into human DNAnature.com
- GC-Mainarep.med.harvard.edu
- Cure all diseasesworksinprogress.news
- A Visual Guide to DNA Sequencingasimov.press
- RNA-based therapeutics: an overview and prospectusnature.com
- Delivering gene therapy’s promise - Dyno Therapeuticsdynotx.substack.com
- Personal genomicsen.wikipedia.org
- A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damagenature.com